Amycretin Peptide: What Is It, How Does It Work, and What Are Its Potential Benefits for Weight Loss?

Amycretin is an experimental peptide being researched for its potential to help with weight loss, appetite control, and blood sugar regulation.

It is being developed by the pharmaceutical company Novo Nordisk, which also makes the weight-loss medicine Wegovy.

Amycretin is also known as Zenagamtide.

What makes Amycretin interesting is that it works on two different hormone systems in the body: GLP-1 and amylin.

Both hormones help control hunger and how much food we eat.

By targeting these two systems together, researchers hope Amycretin could help people feel less hungry, eat smaller portions, and lose weight.

Early clinical trials have shown promising results, but Amycretin is still being studied, and its long-term safety and effectiveness are not yet fully understood.

To understand how Amycretin works, it helps to know about two natural hormones: GLP-1 and amylin.

These hormones send messages between the digestive system and the brain.

Their job is to help the body manage hunger, digestion, and blood sugar.

Amycretin is designed to copy some of these natural signals.

1. GLP-1: Helps Control Hunger

GLP-1 is a hormone released by the intestines after eating.

It helps the body in several ways:

• Sends signals to the brain that help reduce hunger.
• Helps people feel satisfied after eating.
• Slows down how quickly food leaves the stomach.
• Helps regulate blood sugar levels.

GLP-1 is also targeted by weight-loss medicines such as semaglutide.

2. Amylin: Helps You Feel Full

Amylin is another hormone that the body naturally produces.

It is released alongside insulin when we eat.

Its main functions include:

• Helping the brain recognize when the body has eaten enough.
• Supporting feelings of fullness after meals.
• Slowing down stomach emptying.
• Helping control blood sugar after eating.

Think of amylin as a natural signal that tells your brain, "You've eaten enough."

3. Amycretin Combines Both Effects

Amycretin activates both GLP-1 and amylin receptors.

Receptors are parts of cells that receive messages, almost like switches that respond to particular signals.

By activating these receptors, Amycretin may help reduce hunger and increase the feeling of fullness.

Researchers believe that combining these effects could lead to significant weight loss.

Newer scientific studies also describe activity at calcitonin receptors, which are related to the amylin receptor system.

Researchers are studying Amycretin for several possible benefits, particularly related to weight management and metabolic health.

Here are the most important areas being investigated.

1. Weight Loss

The most researched potential benefit of Amycretin is weight loss.

Early human clinical trials have shown that participants receiving Amycretin experienced substantial reductions in body weight.

This may happen because Amycretin helps control hunger and makes people feel satisfied with less food.

In one clinical trial published in The Lancet in 2025, a group receiving weekly Amycretin injections showed an estimated average weight reduction of 24.3% after 36 weeks, compared with 1.1% in the placebo group.

A placebo is an inactive treatment used to help researchers understand whether a medicine is working.

These findings are promising, but the trial was relatively small, and the results should not be interpreted as guaranteed weight loss.

2. Reduced Hunger and Appetite

Another potential benefit is reduced appetite.

Hunger is controlled by several signals travelling between the stomach, intestines, and brain.

Amycretin targets hormone systems that are involved in these signals.

This could make it easier for people to feel satisfied without eating as much.

However, researchers are still studying exactly how these effects translate into long-term appetite control.

3. Feeling Full for Longer

Amycretin may also help people feel full for longer after eating.

Both GLP-1 and amylin influence digestion and fullness.

One of their effects is slowing how quickly food leaves the stomach.

When food stays in the stomach longer, feelings of fullness may last longer.

This could contribute to reduced food intake and weight loss.

4. Better Blood Sugar Control

Amycretin is also being investigated for its effects on blood sugar.

GLP-1 helps the body release insulin when blood sugar rises.

Amylin helps control how quickly nutrients enter the bloodstream after a meal.

Together, these effects may improve blood sugar regulation.

In clinical trials involving people with type 2 diabetes, Amycretin reduced HbA1c, a blood test that measures average blood sugar levels over approximately three months.

These findings suggest potential benefits for people with type 2 diabetes, although larger studies are still needed.

5. Potential Improvements in Metabolic Health

Metabolic health refers to how well the body manages energy, blood sugar, and other processes involved in maintaining health.

Excess body weight is associated with several metabolic health problems.

Because Amycretin has shown effects on body weight and blood sugar, researchers are interested in whether it could also improve other measures of metabolic health.

However, benefits such as preventing heart attacks or reducing long-term cardiovascular risk have not yet been established specifically for Amycretin.

Amycretin has attracted attention because of the results reported in early clinical trials.

Researchers have studied both injectable and oral versions.

Here are some important findings.

These results come from different studies involving different participants, doses, and treatment conditions.

They cannot be directly compared to determine which version works best.

Most importantly, early clinical trial results do not guarantee the same results in larger populations.

Amycretin is often compared with other peptides and medicines being used or investigated for weight management.

Two well-known examples are semaglutide and tirzepatide.

Although these compounds influence some of the same hormone systems, they do not work in exactly the same way.

What Makes Amycretin Different?

The main difference is its combination of GLP-1 and amylin activity.

Semaglutide primarily targets GLP-1 receptors.

Tirzepatide activates both GLP-1 and GIP receptors.

Amycretin is designed to activate GLP-1 and amylin-related receptors together.

Scientists are studying whether this combination could provide additional benefits for weight management.

However, there is not yet enough direct clinical evidence to conclude that Amycretin is better or safer than semaglutide or tirzepatide.

Like other experimental weight-loss treatments, Amycretin may cause side effects.

In clinical trials, the most commonly reported side effects involved the digestive system.

These included:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach discomfort

Many reported side effects were mild or moderate, but some participants experienced more serious problems.

Researchers are still investigating the long-term safety of Amycretin.

Important questions include whether side effects become less common over time, how safe the treatment is during longer use, and what happens after treatment stops.

Because Amycretin is investigational, it should not be treated as an approved or established weight-loss medicine.

Researchers have developed and tested two forms of Amycretin.

Injectable Amycretin

The injectable version has been studied using once-weekly injections.

Clinical trials have investigated its effects on body weight, blood sugar, and side effects.

Oral Amycretin

The oral version is designed to be taken as a tablet.

Researchers are interested in whether an oral treatment could offer a convenient alternative to injections.

Both versions remain under clinical investigation, and their long-term effectiveness and safety require further research.

As of October 2026, Amycretin, also known as Zenagamtide, remains an experimental treatment undergoing clinical development.

It is not an established, approved weight-loss medicine.

Clinical trials are designed to determine whether it is sufficiently effective and safe for medical use.

Products marketed online as research peptides should not be assumed to have the same quality, formulation, or safety profile as the products used in regulated clinical trials.

What Is Amycretin Used For?

Amycretin is being researched primarily as a possible future treatment for obesity and type 2 diabetes.

Scientists are studying its effects on body weight, appetite, fullness, and blood sugar.

Does Amycretin Help With Weight Loss?

Early human studies have demonstrated substantial weight reductions in some treatment groups.

However, more research is needed to understand its long-term results, safety, and effectiveness in larger populations.

How Much Weight Can You Lose With Amycretin?

In one early injectable trial, the highest-dose group had an estimated average weight reduction of 24.3% after 36 weeks.

This was a specific clinical trial result, not a prediction of how much weight an individual would lose.

Does Amycretin Reduce Appetite?

Amycretin activates GLP-1 and amylin-related receptors, which play important roles in appetite and fullness.

Researchers believe these effects contribute to the weight loss observed in clinical trials.

Is Amycretin the Same as Ozempic?

No.

Ozempic contains semaglutide, which primarily activates GLP-1 receptors.

Amycretin is a different experimental molecule that activates both GLP-1 and amylin-related receptor systems.

Is Amycretin Better Than Tirzepatide?

It is too early to say.

Although some early Amycretin studies have reported substantial weight loss, there is not enough direct comparative research to establish whether it is more effective or safer than tirzepatide.

Is Amycretin Safe?

Clinical trials have provided early safety information, but the full safety profile is not yet known.

Digestive side effects, including nausea and vomiting, have been commonly reported.

Longer and larger studies are needed.

What Is the Difference Between Amycretin and Zenagamtide?

They are two names for the same investigational drug.

Zenagamtide is the newer name used in scientific publications and clinical development.

Amycretin is an experimental peptide that has attracted scientific interest because of its potential effects on weight loss, appetite, and blood sugar regulation.

Unlike medicines that target GLP-1 alone, Amycretin combines GLP-1 and amylin-related activity.

This combination may help reduce hunger, increase feelings of fullness, and support weight reduction.

Early human clinical trials have reported promising results, including significant weight loss and improvements in blood sugar measurements.

However, Amycretin is still being studied.

More research is required to establish its long-term safety, effectiveness, and whether it offers meaningful advantages over existing weight-loss treatments.

For now, Amycretin represents a promising area of obesity and metabolic research rather than an established medical treatment.

1. Dahl K, et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet. Read study
2. Gasiorek A, et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. The Lancet. Read study
3. Mora P, et al. (2026). Efficacy and safety of once-weekly subcutaneous zenagamtide in adults with type 2 diabetes: a phase 2 trial. The Lancet. Read study
4. Mora P, et al. (2026). Efficacy and safety of once-daily oral zenagamtide in adults with type 2 diabetes: a phase 2 trial. The Lancet. Read study
5. Khoo B, Tan TMM. (2025). GLP-1 and amylin receptor multiagonism with amycretin for obesity management. The Lancet. Read commentary
6. Novo Nordisk. (2025). Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity. Read announcement
7. Novo Nordisk. (2026). Investigational zenagamtide shows significant HbA1c reductions with up to 14.6% weight loss in adults with type 2 diabetes. Read announcement
8. ClinicalTrials.gov. (2025). Study of injectable Amycretin in people with overweight or obesity, NCT06064006. View trial
9. ClinicalTrials.gov. (2025). First-in-human clinical research on oral Amycretin, NCT05369390. View trial